<DOC>
	<DOCNO>NCT01787903</DOCNO>
	<brief_summary>The purpose study determine effect real-time continuous glucose monitoring glycemia quality life patient type 1 diabetes mellitus impair hypoglycemia awareness .</brief_summary>
	<brief_title>The Effects RT-CGM Glycemia QoL Patients With T1DM IHA</brief_title>
	<detailed_description>The investigator hypothesize use RT-CGM , relative control intervention use masked CGM , result improvement various measure glycemia indicator quality life , reduce occurrence hypoglycemia hyperglycemia restore hypoglycemia awareness T1DM patient IHA . We test hypothesis address follow research question : What effect 16 week RT-CGM use , versus 16 week CGM use , patient T1DM IHA 1 . ( primary objective : ) time spend euglycemia 2 . ( secondary objective : ) - ( diabetes-specific ) marker QoL , cover diabetes-related emotional distress ( PAID-5 ) , fear hypoglycemia ( HFS-2 ) , self-efficacy ( CIDS ) , health status ( EQ5D ) emotional well-being ( WHO-5 ) - glycemia variable , include HbA1c time spend hypo- - hyperglycemia range - incidence duration hypoglycemic episodes - change hypoglycemia awareness score accord Gold et al. , 3 . ( tertiary objective : ) - measure glucose variability - autonomic nervous system balance - duration wear RT-CGM device - patient ' therapy adjustment intervention - hypoglycemia awareness score accord Clarke et al . - satisfaction use CGM - number contact moment plan accord study schedule - absence work patient ( spouse ) - global estimate cost use health care</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Hypoglycemia</mesh_term>
	<mesh_term>Unconsciousness</mesh_term>
	<criteria>T1DM , diagnose accord ADA criterion regardless duration Use multiple daily injection insulin ( basal insulin injection bolus injection ) continuous subcutaneous insulin infusion Any HbA1c Age 18 70 year old ( inclusive ) IHA accord questionnaire Gold et al . Performing least 3 SMBG/day 21 SMBG/week Type 2 diabetes mellitus History ( recent ) major renal , liver , ( ischemic ) heart disease ( include cardiac conduction disorder ) Current untreated proliferative diabetic retinopathy Current ( treatment ) malignancy Current use nonselective betablockers Current psychiatric disorder , include schizophrenia , bipolar disorder , anorexia nervosa bulimia nervosa Substance abuse alcohol abuse ( men &gt; 21 units/week , woman &gt; 14 units/week ) Current pregnancy intention conceive Current use RTCGM short term ( i.e . diagnostic use use shorter 3 consecutive month ) Hearing vision impairment hinder perceive glucose display alarm , otherwise incapable use ( RT ) CGM , opinion investigator Poor commandment Dutch language ( mental ) disorder precludes full understand purpose instruction study Participation another clinical study Known suspect allergy trial product relate product</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Type 1 diabetes mellitus</keyword>
	<keyword>Hypoglycemia unawareness</keyword>
	<keyword>Real-time continuous glucose monitoring</keyword>
	<keyword>Glucose control</keyword>
</DOC>